Liraglutide's Appetite Suppression Shows Minimal Direct Link to Delayed Gastric Emptying
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide are effective treatments for obesity, partly by promoting satiety and reducing appetite. A widely assumed mechanism for GLP-1RA-induced appetite suppression is delayed gastric emptying. However, the direct quantitative contribution of this mechanism to overall appetite reduction has not been clearly established. Understanding the precise actions of these important therapeutics is crucial, as a clearer picture of their mechanisms could inform better treatment strategies and the development of next-generation compounds.
Study Design
Researchers performed a secondary data analysis from a 16-week randomized, placebo-controlled trial (ClinicalTrials.gov identifier: NCT02647944) involving patients with obesity. They examined correlations between solid food gastric emptying and measures of satiation and energy intake. This was done for the entire cohort at baseline and end of treatment, and separately for placebo- and liraglutide-treated groups. They also compared appetitive measures among liraglutide-treated participants categorized by normal, persistently delayed, or transiently delayed gastric emptying patterns during treatment.
Results
At baseline and completion, gastric emptying significantly correlated with energy intake and one satiation parameter in the entire cohort, but this effect was minor.
Gastric emptying accounted for only 4%-6% of the variance in these appetitive measures. Crucially, no such correlations were observed when analyzing the placebo- or liraglutide-treated groups independently. Furthermore, there were no significant differences in appetitive measures among liraglutide-treated subgroups exhibiting normal, persistently delayed, or transiently delayed gastric emptying patterns during treatment. This suggests that while delayed gastric emptying is a known effect of
GLP-1RAs, its direct contribution to liraglutide-induced appetite suppression is limited, pointing to other, more dominant mechanisms at play.
Key Findings
- Gastric emptying correlated with energy intake and satiation in the overall cohort, but accounted for only 4%-6% of the variance.
- No significant correlations between gastric emptying and appetitive measures were found in liraglutide- or placebo-treated groups alone.
- No differences in appetite measures were observed among liraglutide-treated patients with varying gastric emptying patterns.
- Delayed gastric emptying appears to play a minimal direct role in liraglutide-induced appetite suppression.
Why It Matters
This research challenges a long-held assumption about the primary mechanism of GLP-1RAs. For clinicians and individuals using liraglutide, this suggests that delayed gastric emptying is not the main driver of its appetite-suppressing effects. Instead, other central or peripheral mechanisms likely play a more significant role in reducing hunger and energy intake. This finding redirects future research towards identifying these dominant pathways, potentially leading to novel therapeutic targets or improved combination strategies for obesity management. It implies that focusing solely on gastric emptying as a measure of efficacy might be misguided, and other GLP-1R signaling pathways should be prioritized in mechanistic studies.
liraglutide
glp-1ra
obesity
appetite-suppression
gastric-emptying
clinical-trial